The Supreme Court said it will hear arguments on March 26 about how patients can access the commonly used abortion pill, mifepristone.
The Supreme Court agreed Dec. 13 to look at a dispute over the availability of a commonly used abortion pill, mifepristone, making it the first abortion case it will hear since its decision overturning Roe v. Wade last year.
The number of legal abortions provided by virtual-only clinics via abortion pill prescriptions spiked 72% in the year following the Supreme Court’s reversal of Roe v. Wade, according to a report by #WeCount, a research project by the Society of Family Planning, a group that supports legal abortion.
Chemical abortion in the form of the “abortion pill” now accounts for 54% of U.S. abortions in 2022, up from 39% in 2017, according to the Guttmacher Institute, a research organization with historical ties to Planned Parenthood, the nation’s largest abortion provider.
In a two-hour hearing on May 17 looking at the U.S. Food and Drug Administration’s decades-old approval of an abortion pill, federal judges seemed to have a harsher line of questioning for attorneys for the federal government and the drug maker, indicating they might be sympathetic to those challenging the drug’s availability.
A federal appeals court in Louisiana is hearing arguments May 17 about the accessibility of the abortion drug mifepristone.
The Supreme Court on April 21 ruled to preserve nationwide access to a drug used in chemical abortions, rejecting a Texas lower-court restrictions while a lawsuit continues.
The U.S. Supreme Court said it would extend the administrative stay in the abortion pill dispute until April 21, temporarily keeping in place status quo federal regulations regarding the use of an abortion drug, and giving the court additional time to consider a lower court’s ruling to stay the U.S. Food and Drug Administration’s approval of the drug.
The U.S. Supreme Court said April 14 it would temporarily keep in place status quo federal regulations regarding the use of an abortion drug, giving the court additional time to consider a lower court’s ruling to stay the U.S. Food and Drug Administration’s approval of the drug.
A federal appeals court in a 2-1 ruling just before midnight April 12 stopped part of the recent order by a Texas judge to suspend approval of the abortion pill mifepristone but the new ruling also put restrictions on the drug’s use.